MedTrace Logo

Pharmacokinetic Aspects of 25-mg Estradiol Pellet in Climacteric Women

NCT06136208 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-09-08

No results posted yet for this study

Summary

A single center, prospective, open-label clinical study will be conducted, to monitor serum concentration and pharmacokinetic profile after subcutaneous implantation of a 25mg-estradiol bioabsorbable implant in postmenopausal women.

Conditions

  • Climacteric Syndrome
  • Menopause
  • Hypoestrogenism

Interventions

DRUG

s.c 25 mg estradiol pellet

Subcutaneous insertion of 25 mg estradiol pellet.

Sponsors & Collaborators

  • Biòs Farmacêutica

    collaborator UNKNOWN

  • Science Valley Research Institute

    lead OTHER

Principal Investigators

  • André Luiz Malavasi de Oliveira Longo, MD, PhD · Science Valley Research Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
41 Years
Max Age
59 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-12-13
Primary Completion
2024-10-09
Completion
2025-07-30

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06136208 on ClinicalTrials.gov